提示非酒精性脂肪性肝病的慢性肝病患者药物性肝损伤风险可能更高
Patients With Chronic Liver Disease Suggestive of Nonalcoholic Fatty Liver Disease May Be at Higher Risk for Drug-Induced Liver Injury.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-12-20
至今尚无研究系统评估非酒精性脂肪性肝病(NAFLD)患者药物性肝损伤(DILI)风险是否增加。本研究检验提示NAFLD的慢性肝病(CLD)患者中疑似处方药所致DILI的频率是否更高。
要点
- 至今尚无研究系统评估NAFLD患者DILI风险是否增加。
- 本研究检验提示NAFLD的CLD患者中疑似DILI频率是否更高。
- 原文未报告具体样本量、效应量或统计结果。
核心结论
- 提示NAFLD的慢性肝病患者处方药所致疑似DILI的频率可能更高。
研究设计与样本
- 研究设计为检验提示NAFLD的CLD患者中疑似处方药所致DILI频率是否更高的研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To date, there have been no studies that systematically examined if individuals with nonalcoholic fatty liver disease (NAFLD) have an increased risk of drug-induced liver injury (DILI). We conducted a study to test if the frequency of suspected DILI from prescription agents is higher in individuals with chronic liver disease (CLD) suggestive of NAFLD.
来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。
引用
- Lammert C, Imler T, Teal E, et al. Patients With Chronic Liver Disease Suggestive of Nonalcoholic Fatty Liver Disease May Be at Higher Risk for Drug-Induced Liver Injury. Clin Gastroenterol Hepatol. 2018. PMID: 30580093. doi:10.1016/j.cgh.2018.12.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。